Demographic characteristics of the 120 study patients
| . | Placebo (n = 59) . | PEG-rHuMGDF 1 μg/kg (n = 15) . | PEG-rHuMGDF 3 μg/kg (n = 46) . | PEG-rHuMGDF combined (n = 61) . |
|---|---|---|---|---|
| Age | ||||
| Median (range) | 46 (18-84) | 45 (20-61) | 52 (18-79) | 51 (18-79) |
| Gender | ||||
| Male (%) | 24 (41) | 9 (60) | 21 (46) | 30 (49) |
| Female (%) | 35 (59) | 6 (40) | 25 (54) | 31 (51) |
| Race | ||||
| White (%) | 54 (92) | 13 (87) | 46 (100) | 59 (97) |
| Body surface area (m2) | ||||
| Median (range) | 1.8 (1.5-2.5) | 2.0 (1.2-2.2) | 1.8 (1.5-2.4) | 1.9 (1.2-2.4) |
| Diagnosis | ||||
| Breast cancer (%) | 10 (17) | 2 (13) | 9 (20) | 11 (18) |
| Leukemia | ||||
| Acute (%) | 15 (25) | 3 (20) | 15 (34) | 18 (30) |
| Chronic (%) | 8 (14) | 0 | 6 (13) | 6 (10) |
| Lymphoma (%) | 11 (18) | 7 (47) | 6 (13) | 13 (21) |
| Study entry platelet | ||||
| count (× 109/L) | ||||
| Median (range) | 11 (2-25) | 12 (4-20) | 11 (11-22) | 11 (1-22) |
| . | Placebo (n = 59) . | PEG-rHuMGDF 1 μg/kg (n = 15) . | PEG-rHuMGDF 3 μg/kg (n = 46) . | PEG-rHuMGDF combined (n = 61) . |
|---|---|---|---|---|
| Age | ||||
| Median (range) | 46 (18-84) | 45 (20-61) | 52 (18-79) | 51 (18-79) |
| Gender | ||||
| Male (%) | 24 (41) | 9 (60) | 21 (46) | 30 (49) |
| Female (%) | 35 (59) | 6 (40) | 25 (54) | 31 (51) |
| Race | ||||
| White (%) | 54 (92) | 13 (87) | 46 (100) | 59 (97) |
| Body surface area (m2) | ||||
| Median (range) | 1.8 (1.5-2.5) | 2.0 (1.2-2.2) | 1.8 (1.5-2.4) | 1.9 (1.2-2.4) |
| Diagnosis | ||||
| Breast cancer (%) | 10 (17) | 2 (13) | 9 (20) | 11 (18) |
| Leukemia | ||||
| Acute (%) | 15 (25) | 3 (20) | 15 (34) | 18 (30) |
| Chronic (%) | 8 (14) | 0 | 6 (13) | 6 (10) |
| Lymphoma (%) | 11 (18) | 7 (47) | 6 (13) | 13 (21) |
| Study entry platelet | ||||
| count (× 109/L) | ||||
| Median (range) | 11 (2-25) | 12 (4-20) | 11 (11-22) | 11 (1-22) |